Octocog alfa - Shire

Drug Profile

Octocog alfa - Shire

Alternative Names: Advate; Antihemophilic Factor (Recombinant); Factor VIII - Baxter Healthcare; rAHF-PFM; Recombinant anti-haemophilic factor - protein-free method; Recombinant factor VIII - protein-free

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Baxter Healthcare Corporation
  • Developer Baxter Healthcare Corporation; Shire
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
  • Mechanism of Action Factor VIII replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemophilia A

Most Recent Events

  • 05 Mar 2018 Launched for Haemophilia A in India, Brunei (IV) before March 2018
  • 03 Jun 2016 Baxalta has been acquired and merged into Shire
  • 11 Feb 2015 Registered for Haemophilia A in Qatar, Saudi Arabia, Morocco and Algeria (IV) proir to February 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top